Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1134/S0012496614010013 | DOI Listing |
Org Biomol Chem
January 2025
Department of Pharmaceutical & Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia 30602, USA.
Bacterial biofilms are surface-attached communities consisting of non-replicating persister cells encased within an extracellular matrix of biomolecules. Unlike bacteria that have acquired resistance to antibiotics, persister cells enable biofilms to demonstrate innate tolerance toward all classes of conventional antibiotic therapies. It is estimated that 50-80% of bacterial infections are biofilm associated, which is considered the underlying cause of chronic and recurring infections.
View Article and Find Full Text PDFVaccine
January 2025
Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos /Bio-Manguinhos, Avenida Brasil 4365, 21040-900 Rio de Janeiro, RJ, Brazil. Electronic address:
Yellow fever (YF) is a viral disease that affects both humans and non-human primates (NHPs). Neotropical monkeys are more severely stricken by YF and the impact of the disease can be devastating to the endangered golden-headed lion tamarins (GHLTs, Leontopithecus chrysomelas). Susceptible GHLTs were immunized with the commercial Brazilian YF 17DD live attenuated vaccine or two other experimental non-replicating YF vaccines: a purified whole-virus, b-propiolactone-inactivated vaccine and a plant-derived recombinant subunit vaccine.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup 56212, Republic of Korea. Electronic address:
Granulomas, dense clusters of immune cells and bacteria, are critical barriers in tuberculosis (TB) treatment. Recent advancements in TB management have highlighted granuloma control as a potential host-directed therapy (HDT) strategy. Although isoniazid (INH) is the first-line drug for TB therapy, its efficacy is limited to non-replicating Mycobacterium tuberculosis (Mtb) under granulomatous conditions, necessitating the development of more effective derivatives.
View Article and Find Full Text PDFbioRxiv
December 2024
Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455.
Pyrazinamide (PZA) is a critical component of tuberculosis first-line therapy due to its ability to kill both growing and non-replicating drug-tolerant populations of within the host. Recent evidence indicates that PZA acts through disruption of coenzyme A synthesis under conditions that promote cellular stress. In contrast to its bactericidal action , PZA shows weak bacteriostatic activity against in axenic culture.
View Article and Find Full Text PDFMol Ther Oncol
December 2024
Center for Discovery in Cancer Research, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!